玻璃化
保持生育能力
体外成熟
低温保存
卵母细胞
卵母细胞冷冻保存
男科
生物
体外受精
胚胎冷冻保存
胚胎
妇科
生育率
医学
人口
细胞生物学
环境卫生
作者
Mohammad Ali Khalili,Abbas Shahedi,Sareh Ashourzadeh,Stefania Annarita Nottola,Guido Macchiarelli,Maria Grazia Palmerini
标识
DOI:10.1007/s10815-017-1005-4
摘要
The use of immature oocytes subjected to in vitro maturation (IVM) opens interesting perspectives for fertility preservation where ovarian reserves are damaged by pathologies or therapies, as in PCO/PCOS and cancer patients. Human oocyte cryopreservation may offer some advantages compared to embryo freezing, such as fertility preservation in women at risk of losing fertility due to oncological treatment or chronic disease, egg donation and postponing childbirth. It also eliminates religious and/or other ethical, legal, and moral concerns of embryo freezing. In addition, a successful oocyte cryopreservation program could eliminate the need for donor and recipient menstrual cycle synchronization. Recent advances in vitrification technology have markedly improved the oocyte survival rate after warming, with fertilization and implantation rates comparable with those of fresh oocytes. Healthy live births can be achieved from the combination of IVM and vitrification, even if vitrification of in vivo matured oocytes is still more effective. Recently, attention is given to highlight whether vitrification procedures are more successful when performed before or after IVM, on immature GV-stage oocytes, or on in vitro matured MII-stage oocytes. In this review, we emphasize that, even if there are no differences in survival rates between oocytes vitrified prior to or post-IVM, reduced maturation rates of immature oocytes vitrified prior to IVM can be, at least in part, explained by underlying ultrastructural and biomolecular alterations.
科研通智能强力驱动
Strongly Powered by AbleSci AI